Psilocybin is a molecule with significant potential for the treatment of mental disorders such as depression, anxiety, post-traumatic stress disorder, and substance abuse. In this study, it was explored the extraction of psilocybin from Psilocybe cubensis mushrooms using a factorial design approach, along with the physicochemical and phytochemical characterization of the extracted material,...
Psychedelic-assisted therapies have re-emerged as a subject of increasing scientific and clinical interest in psychiatry, particularly in the context of persistent treatment gaps for conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. Compounds, including psilocybin and 3,4-methylenedioxymethamphetamine, are being evaluated in...
Abstract Background Psychedelic-assisted psychotherapy has shown potential for psychiatric disorders. However, the magnitude of symptom change in control groups remains poorly understood. We aim to evaluate within-group effects in control groups and compare them to treatment groups in psychedelic trials. Methods A systematic search was conducted up to 1 July 2025. The study protocol was...
The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-N-methamphetamine (MDMA). The study provided an overview of PAT as currently provided in Switzerland under the regulatory framework of the Federal Office of Public Health (FOPH)....
While tele-mental health has improved access to standard medication management and psychotherapy for rural Veterans, implementation of interventional psychiatry treatments will require in-person care, potentially leading to the exacerbation of rural-urban disparities in access to mental health care. We studied the availability of interventional psychiatry treatments, delivered clinically or in...
Psychedelic-assisted psychotherapy (PAP) is emerging as a novel intervention for major psychiatric disorders, most notably major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). While psychotherapy is widely regarded as a core element of PAP its precise role remains poorly defined. This narrative review traces the development of PAP within contemporary Western psychiatry,...
BACKGROUND: Psychedelics such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin are showing promising results in clinical trials for the treatment of mental health disorders, including post-traumatic stress disorder, addiction, and treatment-resistant depression. US Food and Drug Administration approval may be on the horizon. Yet, little is known about how these treatments will move...
Psychotherapy process research increasingly uses intensive longitudinal monitoring to capture dynamic patterns of change in patients. In this study, 283 psychiatric inpatients diagnosed with depression (n = 70), PTSD (n = 148), dissociative disorders (n = 26) or personality disorders (n = 39) completed the Therapy Process Questionnaire each evening over an average of 81.5 days per patient,...
DOI: https://doi.org/10.26565/2074-8922-2025-85-19 The purpose of the article is to evaluate the efficiency of mindfulness practices in the psychological rehabilitation of military personnel and war veterans in the context of the current war in Ukraine and to determine the possibilities for their integration into Ukrainian rehabilitation programs. Methods. The methods used include reviewing...
Farmacja PolskaDecember 30, 2025Ewa Niedzielska-Andres, Angelika Ziaja, Stanisław Zielinski et al.
Przedmiot badań: W ostatnich latach obserwuje się rosnące zainteresowanie wykorzystaniem naturalnych halucynogenów w leczeniu zaburzeń psychicznych, uzależnień czy bólu. Substancje takie jak psylocybina, ayahuasca, ibogaina czy meskalina poddawane są ocenie w badaniach klinicznych, które wskazują na ich potencjał terapeutyczny, zwłaszcza w leczeniu depresji lekoopornej, zespołu stresu...